Northern Trust’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $47.1M | Buy |
863,091
+60,910
| +8% | +$3.21M | 0.01% | 1231 |
|
|
2026
Q1 | $38.2M | Buy |
802,181
+47,076
| +6% | +$2.48M | 0.01% | 1273 |
|
|
2025
Q4 | $39.6M | Sell |
755,105
-24,825
| -3% | -$1.49M | 0.01% | 1254 |
|
|
2025
Q3 | $50.5M | Buy |
779,930
+18,815
| +2% | +$1.08M | 0.01% | 1122 |
|
|
2025
Q2 | $37M | Buy |
761,115
+523,467
| +220% | +$20.3M | 0.01% | 1278 |
|
|
2025
Q1 | $8.09M | Sell |
237,648
-19,520
| -8% | -$827K | ﹤0.01% | 2164 |
|
|
2024
Q4 | $10.1M | Buy |
257,168
+29,416
| +13% | +$1.39M | ﹤0.01% | 2112 |
|
|
2024
Q3 | $10.7M | Sell |
227,752
-5,659
| -2% | -$287K | ﹤0.01% | 2026 |
|
|
2024
Q2 | $12.6M | Sell |
233,411
-9,867
| -4% | -$571K | ﹤0.01% | 1858 |
|
|
2024
Q1 | $16.6M | Sell |
243,278
-7,155
| -3% | -$512K | ﹤0.01% | 1714 |
|
|
2023
Q4 | $15.7M | Buy |
250,433
+6,185
| +3% | +$342K | ﹤0.01% | 1789 |
|
|
2023
Q3 | $11.1M | Buy |
244,248
+5,085
| +2% | +$263K | ﹤0.01% | 1926 |
|
|
2023
Q2 | $13.4M | Buy |
239,163
+40,289
| +20% | +$2.29M | ﹤0.01% | 1858 |
|
|
2023
Q1 | $9M | Buy |
198,874
+10,232
| +5% | +$497K | ﹤0.01% | 2090 |
|
|
2022
Q4 | $7.67M | Sell |
188,642
-10,122
| -5% | -$537K | ﹤0.01% | 2189 |
|
|
2022
Q3 | $13M | Buy |
198,764
+14,533
| +8% | +$1.05M | ﹤0.01% | 1797 |
|
|
2022
Q2 | $11.2M | Buy |
184,231
+18,621
| +11% | +$1.09M | ﹤0.01% | 1945 |
|
|
2022
Q1 | $10.4M | Buy |
165,610
+122,302
| +282% | +$7.68M | ﹤0.01% | 2125 |
|
|
2021
Q4 | $3.28M | Buy |
43,308
+1,007
| +2% | +$88K | ﹤0.01% | 2963 |
|
|
2021
Q3 | $4.74M | Sell |
42,301
-10,180
| -19% | -$1.28M | ﹤0.01% | 2770 |
|
|
2021
Q2 | $8.5M | Sell |
52,481
-7,394
| -12% | -$899K | ﹤0.01% | 2486 |
|
|
2021
Q1 | $7.29M | Buy |
59,875
+11,962
| +25% | +$1.81M | ﹤0.01% | 2501 |
|
|
2020
Q4 | $7.34M | Buy |
47,913
+2,500
| +6% | +$295K | ﹤0.01% | 2450 |
|
|
2020
Q3 | $3.8M | Buy |
45,413
+5,344
| +13% | +$474K | ﹤0.01% | 2709 |
|
|
2020
Q2 | $2.94M | Buy |
40,069
+3,976
| +11% | +$232K | ﹤0.01% | 2822 |
|
|
2020
Q1 | $1.53M | Buy |
36,093
+2,039
| +6% | +$105K | ﹤0.01% | 3003 |
|
|
2019
Q4 | $2.07M | Buy |
34,054
+2,321
| +7% | +$127K | ﹤0.01% | 3115 |
|
|
2019
Q3 | $1.3M | Buy |
31,733
+655
| +2% | +$31.3K | ﹤0.01% | 3305 |
|
|
2019
Q2 | $1.46M | Buy |
31,078
+2,188
| +8% | +$87.4K | ﹤0.01% | 3215 |
|
|
2019
Q1 | $1.03M | Buy |
28,890
+6,683
| +30% | +$231K | ﹤0.01% | 3346 |
|
|
2018
Q4 | $634K | Sell |
22,207
-6,110
| -22% | -$212K | ﹤0.01% | 3501 |
|
|
2018
Q3 | $1.25M | Buy |
28,317
+4,196
| +17% | +$220K | ﹤0.01% | 3406 |
|
|
2018
Q2 | $1.42M | Buy |
24,121
+8,241
| +52% | +$469K | ﹤0.01% | 3365 |
|
|
2018
Q1 | $726K | Buy |
+15,880
| New | +$655K | ﹤0.01% | 3468 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
Northern Trust's CRSP Position: Q2 2026 in Review
Northern Trust increased its CRISPR Therapeutics (CRSP) stake by 7.6% in Q2 2026, buying an estimated $3.21M and bringing the position to 863,091 shares worth $47.1M. The position accounts for 0.01% of the portfolio, ranked #1231.
Northern Trust first reported a position in CRSP in Q1 2018 and has held it in 34 quarters since. The position peaked at $50.5M in Q3 2025. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.
- Northern Trust held 863,091 shares of CRISPR Therapeutics worth $47.1M as of Q2 2026.
- Northern Trust bought 60,910 CRISPR Therapeutics shares in Q2 2026, an estimated $3.21M.
- CRISPR Therapeutics made up 0.01% of Northern Trust's portfolio in Q2 2026, its #1231 holding.
- Northern Trust first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 34 quarters since.
- Northern Trust's CRISPR Therapeutics position peaked at $50.5M in Q3 2025.
- 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.
Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.